Dexibuprofen Strides

What Is Dexibuprofen Strides and What Is It Used For?

Dexibuprofen Strides is a prescription non-steroidal anti-inflammatory drug (NSAID) containing 200 mg of dexibuprofen per film-coated tablet. It is used to treat mild to moderate pain, reduce inflammation, and lower fever in a range of conditions including osteoarthritis, rheumatoid arthritis, dysmenorrhoea, dental pain, and musculoskeletal disorders.

Dexibuprofen is the pharmacologically active S(+)-enantiomer of the widely used NSAID ibuprofen. Racemic ibuprofen, the form commonly sold worldwide, is a 50:50 mixture of two mirror-image molecules: the active S(+)-enantiomer and the largely inactive R(-)-enantiomer. By isolating and formulating only the active S(+)-form, dexibuprofen delivers the same therapeutic benefit at roughly half the dose of racemic ibuprofen. For example, 200 mg of dexibuprofen provides anti-inflammatory and analgesic effects comparable to approximately 400 mg of standard ibuprofen.

The mechanism of action of dexibuprofen, like other NSAIDs, involves the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are responsible for converting arachidonic acid into prostaglandins, which are lipid mediators involved in inflammation, pain signalling, and thermoregulation. By reducing prostaglandin synthesis, dexibuprofen effectively decreases the cardinal signs of inflammation: swelling, redness, heat, and pain. It also acts centrally and peripherally to reduce fever and attenuate pain perception.

Dexibuprofen Strides is manufactured by Strides Pharma Science Limited and is available as film-coated tablets for oral administration. The film coating is designed to protect the active ingredient and facilitate swallowing. This formulation is intended for short-term symptomatic treatment of pain and inflammation, although it may be prescribed for longer periods under close medical supervision in chronic conditions such as osteoarthritis or rheumatoid arthritis.

Clinical studies, including randomised controlled trials published in peer-reviewed journals, have demonstrated that dexibuprofen provides onset of analgesia within 30 to 60 minutes of oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The elimination half-life is approximately 1.8 to 3.5 hours, similar to that of racemic ibuprofen. Some research suggests that the use of the pure S(+)-enantiomer may be associated with a somewhat improved gastrointestinal safety profile compared with racemic ibuprofen, although this remains a subject of ongoing clinical evaluation.

What Should You Know Before Taking Dexibuprofen Strides?

Before taking Dexibuprofen Strides, it is essential to inform your doctor about your complete medical history, including any history of gastrointestinal ulcers, cardiovascular disease, kidney or liver impairment, and all medications you are currently taking. This NSAID is contraindicated in several conditions and carries important warnings.

Contraindications

You must not take Dexibuprofen Strides if any of the following apply to you:

• Known hypersensitivity to dexibuprofen, ibuprofen, or any of the excipients in the formulation
• History of bronchospasm, urticaria, or rhinitis triggered by aspirin or other NSAIDs (sometimes called the “aspirin triad” or Samter’s syndrome)
• Active peptic ulcer or history of recurrent gastrointestinal ulceration or bleeding (two or more distinct episodes of proven ulceration or bleeding)
• Severe hepatic failure, severe renal failure, or severe heart failure (NYHA Class IV)
• Third trimester of pregnancy due to risk of premature closure of the ductus arteriosus and potential complications during labour and delivery
• Active gastrointestinal bleeding or other active bleeding disorders, including cerebrovascular haemorrhage
• During or immediately after coronary artery bypass graft (CABG) surgery

Warnings and Precautions

Dexibuprofen Strides should be used with particular caution in the following circumstances, and your doctor may need to adjust your dose, monitor you more closely, or choose an alternative treatment:

• Cardiovascular risk: NSAIDs, including dexibuprofen, may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. This risk may increase with longer duration of use and in patients with pre-existing cardiovascular disease or risk factors such as hypertension, hyperlipidaemia, diabetes, and smoking. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both advise using the lowest effective dose for the shortest possible duration.
• Gastrointestinal risk: NSAIDs are associated with an increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time during therapy, with or without warning symptoms, and may be fatal. Elderly patients and those with a prior history of peptic ulcer disease are at higher risk. Concomitant use of a proton pump inhibitor (PPI) such as omeprazole should be considered for high-risk patients.
• Renal impairment: NSAIDs may cause renal papillary necrosis and other renal injury. Patients at greatest risk include those with pre-existing renal impairment, heart failure, liver dysfunction, those taking diuretics or ACE inhibitors, and elderly patients. Kidney function should be monitored, especially with prolonged use.
• Hepatic impairment: Patients with mild to moderate hepatic impairment should use dexibuprofen with caution. Elevations of liver enzymes (ALT, AST) have been reported with NSAID use. If clinical signs of liver disease develop, treatment should be discontinued.
• Elderly patients: Older adults are more susceptible to the adverse effects of NSAIDs, particularly gastrointestinal bleeding and renal complications. Use the lowest effective dose for the shortest duration necessary.
• Asthma: Patients with asthma, especially those with nasal polyps, may be at increased risk of bronchospasm when taking NSAIDs.
• Fluid retention and oedema: NSAIDs can cause fluid retention and oedema. Use with caution in patients with heart failure or hypertension.

Pregnancy and Breastfeeding

The use of dexibuprofen during pregnancy requires careful consideration and medical guidance. The safety profile varies by trimester:

• First and second trimester: Dexibuprofen should only be used if the potential benefit justifies the potential risk to the fetus. The lowest effective dose should be used for the shortest possible duration. Some epidemiological data suggest a slightly increased risk of miscarriage and cardiac malformations after NSAID use during early pregnancy, although the absolute risk remains low.
• Third trimester (contraindicated): Dexibuprofen is strictly contraindicated in the third trimester. Use during this period may cause premature closure of the ductus arteriosus in the fetus, which can lead to persistent pulmonary hypertension in the newborn. It may also inhibit uterine contractions, potentially prolonging labour and increasing the risk of maternal and neonatal bleeding.
• Breastfeeding: Dexibuprofen, like ibuprofen, passes into breast milk in very small amounts. At therapeutic doses, the amount transferred to the infant is considered negligible. However, it is generally recommended to use the lowest effective dose for the shortest duration and to consult your doctor before taking this medication while breastfeeding.

How Does Dexibuprofen Strides Interact with Other Drugs?

Dexibuprofen Strides interacts with a number of commonly prescribed medications. The most clinically significant interactions involve anticoagulants, other NSAIDs, lithium, methotrexate, and antihypertensive drugs. Always inform your doctor and pharmacist about all medicines, supplements, and herbal products you are taking.

Drug interactions with dexibuprofen follow the same profile as racemic ibuprofen and other NSAIDs, as the pharmacological effects are driven by the same mechanism of cyclooxygenase inhibition and prostaglandin synthesis reduction. The following table summarises the most important drug interactions. Some interactions can be managed with dose adjustments or monitoring, while others may require avoidance of the combination entirely.

Major Interactions

Minor Interactions

It is also important to note that alcohol consumption while taking dexibuprofen increases the risk of gastrointestinal bleeding and should be minimised or avoided. Herbal supplements such as ginkgo biloba, garlic, and ginger may also increase bleeding risk when combined with NSAIDs.

What Is the Correct Dosage of Dexibuprofen Strides?

The dosage of Dexibuprofen Strides depends on the condition being treated, the patient’s age, weight, and overall health. The general principle for all NSAID therapy is to use the lowest effective dose for the shortest possible duration. The standard adult dose is 200–400 mg two to three times daily.

Dosing recommendations for dexibuprofen are based on clinical trial data and regulatory guidelines from the European Medicines Agency (EMA). Because dexibuprofen is the active enantiomer, doses are approximately half those of racemic ibuprofen. The tablets should be swallowed whole with a glass of water, preferably with or after food to reduce the risk of gastrointestinal irritation.

Adults

Children

Elderly

Missed Dose

If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose entirely and continue with your regular dosing schedule. Do not take a double dose to compensate for a missed one. Taking a double dose increases the risk of side effects, particularly gastrointestinal problems. If you are unsure about what to do, contact your doctor or pharmacist for guidance.

Overdose

In the event of an overdose, seek immediate medical attention or contact your local poison control centre. Symptoms of NSAID overdose may include nausea, vomiting, abdominal pain, drowsiness, headache, tinnitus, and in severe cases, gastrointestinal bleeding, metabolic acidosis, renal failure, and central nervous system depression. Treatment is primarily supportive and symptomatic. There is no specific antidote for dexibuprofen overdose. Activated charcoal may be considered if the patient presents within one hour of ingestion. Haemodialysis is unlikely to be of benefit as dexibuprofen is highly protein-bound.

What Are the Side Effects of Dexibuprofen Strides?

Like all NSAIDs, Dexibuprofen Strides can cause side effects, although not everybody gets them. The most common side effects are gastrointestinal in nature, including nausea, dyspepsia, and abdominal pain. Serious but less common side effects include gastrointestinal bleeding, cardiovascular events, and renal impairment.

The side effect profile of dexibuprofen is broadly similar to that of racemic ibuprofen and other NSAIDs. However, some clinical studies suggest that the pure S(+)-enantiomer may cause fewer gastrointestinal adverse events per unit of therapeutic effect, likely because lower total drug doses are required. The following frequency classification is based on the convention used by the World Health Organization (WHO) and the European Medicines Agency (EMA).

The risk of gastrointestinal side effects is generally dose-dependent and increases with longer duration of treatment. Patients with a history of peptic ulcer disease, gastrointestinal bleeding, or those concurrently taking corticosteroids, anticoagulants, or SSRIs are at particularly elevated risk. Protective therapy with a proton pump inhibitor (PPI) is recommended for these high-risk groups by both the British National Formulary (BNF) and EMA guidelines.

Cardiovascular side effects, including myocardial infarction and stroke, have been associated with NSAID use in large-scale observational studies and meta-analyses. A landmark 2013 meta-analysis published in The Lancet (Coxib and traditional NSAID Trialists' Collaboration) found that high-dose NSAID use was associated with approximately one-third increase in the risk of major vascular events. The risk is generally lower with ibuprofen (and by extension dexibuprofen) at standard doses compared with diclofenac, but caution remains warranted, especially in patients with existing cardiovascular disease.

How Should You Store Dexibuprofen Strides?

Store Dexibuprofen Strides at room temperature below 25°C (77°F) in the original packaging to protect from moisture and light. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of medications is essential to maintain their efficacy and safety. Dexibuprofen Strides film-coated tablets should be stored under the following conditions:

• Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
• Moisture: Keep in the original blister packaging or container to protect from moisture. Do not transfer tablets to a different container unless it provides equivalent protection.
• Light: Protect from direct sunlight and strong artificial light.
• Accessibility: Store in a secure location out of the sight and reach of children and pets.
• Expiry date: Do not use the tablets after the expiry date (EXP) printed on the blister pack and outer carton. The expiry date refers to the last day of that month.

Do not dispose of unused or expired medications via household waste or down the drain. Return them to your pharmacist or local collection point for safe disposal. This helps protect the environment and prevents accidental ingestion by children, pets, or wildlife. Many countries have national take-back programmes for unused pharmaceuticals; consult your local pharmacy or waste management authority for specific guidance in your area.

What Does Dexibuprofen Strides Contain?

Each film-coated tablet of Dexibuprofen Strides contains 200 mg of dexibuprofen as the active substance, along with several inactive ingredients (excipients) that help form, stabilise, and coat the tablet.

The active substance is dexibuprofen (200 mg per tablet), which is the S(+)-enantiomer of ibuprofen. The excipients (inactive ingredients) typically found in film-coated tablet formulations of this type include:

• Tablet core: Microcrystalline cellulose (binder and filler), croscarmellose sodium (disintegrant to aid tablet break-up), hypromellose (binder), silica colloidal anhydrous (glidant), magnesium stearate (lubricant)
• Film coating: Hypromellose, titanium dioxide (E171, white colouring agent), macrogol (plasticiser), talc

The film coating serves several purposes: it protects the active ingredient from degradation by moisture and light, masks any unpleasant taste, and facilitates easier swallowing. The tablets are white to off-white, round or oblong in shape, and biconvex. They may bear an identifying imprint or score line depending on the specific packaging batch.

If you have known allergies or intolerances to any of these excipients, inform your doctor or pharmacist before taking this medication. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should note that some formulations may contain lactose; however, the standard Dexibuprofen Strides formulation does not list lactose as an excipient. Always check the patient information leaflet included in the packaging for the most up-to-date and complete list of ingredients.

Frequently Asked Questions about Dexibuprofen Strides